Ⅲ期非小细胞肺癌调强放疗不勾画临床靶区的初步研究  

Preliminary research on stage Ⅲ non-small cell lung cancer patients treated with intensity-modulated radiotherapy without delineation of clinical target volume

作　　者：梁香存[1] 王庆[1] 梁凯[2] 才虹美[1] 梁健[1] 张红斌[1] 赵敏[1] 

机构地区：[1]河北省胸科医院肺肿瘤二科,河北石家庄050041 [2]石家庄经济学院职工医院,河北石家庄050031

出　　处：《实用临床医药杂志》2016年第7期31-33,共3页Journal of Clinical Medicine in Practice

摘　　要：目的研究Ⅲ期非小细胞肺癌调强放疗不勾画临床靶区的可行性。方法 80例行调强放疗的Ⅲ期非小细胞肺癌患者,随机分为研究组（不勾画临床靶区）和对照组（勾画临床靶区）。比较2组患者的疗效及毒副反应。结果 2组有效率、局部复发率、远处转移率、1年生存率均无显著差异（P〉0.05）,而3~4级放射性肺炎发生率有显著差异（P〈0.05）。结论Ⅲ期非小细胞肺癌调强放疗不勾画临床靶区并未增加局部复发率、远处转移率及降低1年生存率,但3~4级放射性肺炎发生率显著降低。Objective To explore the feasibility of omitting delineation of clinical target volume for stage Ⅲ non-small cell lung cancer（ NSCLC） patients treated with intensity-modulated radiotherapy. Methods Eigthy patients with stage Ⅲ NSCLC were treated with IMRT. They were randomly divided into study group（ without delineation of clinical target volume） and control group（ delineation of clinical target volume）. Clinical efficacy and adverse reactions were compared between two groups. Results There were no significant differences in effective rate,the local relapse rate,the rate of distant metastases and the l-year survival rate between two groups（ P〈0. 05）,but there was significant difference in incidence rate of grade 3 to 4 radiation pneumonia（ P〈0. 05）. Conclusion Without delineation of clinical target volume for stage Ⅲ non-small cell lung cancer（ NSCLC）patients treated with intensity-modulated radiotherapy dose not increase the local relapse rate and the rate of distant metastasis as well as reduce the 1 year survival rate,but the incidence rate of grade 3to 4 radiation pneumonia decrease significantly.

关 键 词：Ⅲ期非小细胞肺癌 调强放疗 临床靶区 放射性肺炎 

分 类 号：R734.2[医药卫生—肿瘤]